Cytochrome P450 3A2 and PGP-MDR1-Mediated Pharmacokinetic Interaction of Sinapic Acid with Ibrutinib in Rats: Potential Food/Herb–Drug Interaction

Ibrutinib (IBR) metabolism (primarily by CYP3A enzyme) is the main route of excretion for IBR, which could lead to drug–drug/herb–drug interactions with herbal medicines, nutritional supplements, and other foods. Sinapic acid (SA) a bioactive phytonutrient that used as dietary supplement treat variety illnesses. Pharmacokinetic may occur when IBR interacts SA, influences pharmacokinetic processes such absorption, distribution, metabolism, excretion. Therefore, it obligatory investigate safety apprehensions parallel usage evaluate possible impact SA on pharmacokinetics propose interaction mechanism in an animal model. The concentration plasma samples was determined using validated UHPLC-MS/MS method after administration single oral dosage (50 mg/kg) rats or without pretreatment (40 mg/kg p.o. each day 7 days, n = 6). co-administration displayed significant increases Cmax ~18.77%, AUC0–T ~28.07%, MRT ~16.87%, Kel ~24.76%, decrease volume distribution Vz/F_obs ~37.66%, rate clearance (Cl/F) ~21.81%, T½ ~20.43%, respectively, were observed compared administered alone, result increased bioavailability IBR. liver intestines significantly inhibited given, increase absorption These findings need be investigated further before they can clinical practice.